logo
Plus   Neg
Share
Email

Janssen's Daratumumab SNDA In Japan Triggers $2 Mln Milestone Payment To Genmab

Danish biotechnology company Genmab A/S announced Thursday that Janssen Pharmaceutical K.K. has submitted a supplemental new drug application or sNDA in Japan for Daratumumab to use in front line Multiple Myeloma. The submission of the application triggers a milestone payment of $2 million to Genmab from Janssen.

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab.

The sNDA application was submitted to the Ministry of Health, Labor and Welfare or MHLW in Japan, for the use of daratumumab (DARZALEX) in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant or ASCT.

The application will receive a priority review. The submission was based on data from the Phase III ALCYONE study that showed a reduction of the risk of disease progression or death by 50 percent in newly diagnosed ASCT ineligible multiple myeloma patients when daratumumab is combined with bortezomib, melphalan and prednisone.

This data was presented as a Late-Breaking Abstract at the 2017 American Society of Hematology (ASH) Annual Meeting and published in The New England Journal of Medicine in December, 2017.

In February 2018, the MHLW granted Orphan Drug Designation to DARZALEX for patients with newly diagnosed multiple myeloma. In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Department of Transportation or DOT is scrutinizing the development of Boeing 737 Max jetliners that were involved in two fatal crashes in five months, the Wall Street Journal reported Sunday, citing people familiar with the matter. Shares of Boeing are declining more than 2 percent in the regular trading session following the report. Shares of Worldpay, Inc. were gaining around 12 percent in London after the eCommerce and payments technology company announced its agreement to be merged with FIS, a U.S. financial services technology company. The combination of stock and cash values Worldpay at an enterprise value of approximately $43 billion, including the assumption of Worldpay debt. Germany's two biggest lenders, Deutsche Bank (DB) and Commerzbank (CRZBY.PK) Sunday confirmed they are in discussions to potential merge.
Follow RTT